Digital pathology has been instrumental in accelerating preclinical R&D workflows to maximize efficiency and quality gains in routine operations, streamline collaboration and improve the reproducibility of results. In this webinar, the featured speakers will dive into the current and future state of histopathology and histology R&D.
During this engaging webinar, attendees will explore:
- The journey of digital pathology and artificial intelligence (AI) adoption for histology and histopathology R&D
- Key considerations and drivers for digital pathology technology investments to help drive therapeutic innovation
Join this webinar to explore the transformative impact of digital pathology and AI in preclinical R&D services.
Richard Bouffard, Director of Histology Lab, Virscio
An ASCP-certified histotechnologist and technologist in molecular biology, Richard Bouffard holds a Bachelor of Science degree from the University of Connecticut in Molecular and Cell Biology. After 10 years in anatomic pathology in the clinical field at Yale, Rich joined Virscio as the first team member of their Pathology and Tissue Pharmacodynamics division. In this capacity, Rich is deeply involved in assay development and optimization, ocular and CNS histopathology, special stains and digital pathology.
Jennifer A. Cann, DVM, PhD, DACVP, Director of Pathology, Virscio
A board-certified veterinary pathologist with a PhD degree in molecular and cellular pathobiology, Jennifer Cann has more than 18 years of experience as an Anatomic Pathologist in academic and biopharmaceutical settings. As the Director of Pathology for Virscio, she provides exploratory and translational pathology support for drug development research at all stages of the pipeline from preclinical through life cycle management, including clinical trial biopsy analysis to demonstrate pharmacodynamic effects within the target tissue.
Golnaz Jalalahmadi, PhD, Image Analysis Research Scientist, Virscio
Golnaz Jalalahmadi graduated from The University of Akron in 2013 with a master’s in physics, where she developed an experimental and computational model to measure the angle between different drugs’ droplets with skin cells in order to understand the interactions of the cells with each drug. She earned a PhD in imaging science from Rochester Institute of Technology in Rochester NY, where she developed a comprehensive workflow utilizing image processing, biomechanics and machine learning techniques to predict the rupture risk for abdominal aortic aneurysm patients. Jalalahmadi joined Virscio at the beginning of 2023 as an Image Analysis Research Scientist. In this role, she applies different image analysis and artificial intelligence methods to digitally quantify the efficiency of different drugs and biomarkers from various staining modalities including hematoxylin and eosin (H&E), immunohistochemistry (IHC) and Immunofluorescence (IF).
Nathan Buchbinder, Co-Founder & Chief Product Officer, Proscia
Nathan Buchbinder is co-founder and Chief Product Officer at Proscia, a leader in digital and computational pathology solutions, where he drives strategy and innovation for the company’s platform and AI product lines. Under his direction, Proscia’s digital pathology platform has powered a complete modernization for leading life sciences organizations and diagnostic laboratories. Nathan holds a bachelor’s degree in biomedical engineering from Johns Hopkins University and a master’s degree in biomedical innovation and development from the Georgia Institute of Technology.
Who Should Attend?
Scientists, pathologists, laboratory personnel in pharmaceutical and biotech companies, CROs and other life sciences organizations interested in the latest trends and technologies in digital pathology.
What You Will Learn
This webinar offers valuable insights into how digital pathology advances preclinical R&D and improves the quality and efficiency of pathology workflows. Attendees will:
- Discover the current status of histopathology R&D and explore key considerations and strategies for digital pathology adoption to streamline routine operations, improve result reproducibility and leverage pathology data
- Explore future state of technology adoption with use cases of artificial intelligence (AI) for histology and histopathology
- Gain insights into real-world use cases and examples of modernized workflows that drive quality and efficiency gains using digital pathology
Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.